Jul. 29 at 3:21 PM
$IPA 2. AI Revenue Still Nascent
Only ~5% of revenue currently from AI (LENSai) – still in early adoption phase despite major positioning shift.
Unclear timeline for significant monetization beyond pilot/partnership phases.
3. Dependence on Few Key Segments
BioStrand is driving margin and optimism; overreliance could be risky if growth slows.
GLP-1 and dengue are promising, but still preclinical – no short-term revenue impact.
4. Oncology Deal Timing
$8M deal not upfront: recognition tied to delivery milestones.
Company expects visible impact in Q2 FY26, but unclear if remaining payments will spread evenly or backloaded.
5. Regulatory Adoption Lag
While FDA is signaling openness to AI-based preclinical models, full regulatory shift is “a few years out.”
LENSai's in silico models currently augment, not replace, traditional IND packages.
